Announcement No. 04/2014 2 May 2014 Coloplast makes provision of DKK 1bn for litigation in the USA

Today Coloplast has decided to make a provision of DKK 1bn to cover potential set- tlements and other costs in connection with litigation in the USA. The provision amounts to DKK 755m after tax.
In addition to the provision, Coloplast has a product liability insurance of DKK 500m, which brings the total expected costs in connection with litigation in the USA to around DKK 1.5bn.
Since 2011, Coloplast has been named as a defendant in individual lawsuits in var i- ous federal and state courts around the United States, alleging injury resulting from use of transvaginal surgical mesh products designed to treat pelvic organ prolapsed and stress urinary incontinence. Coloplast expects around 7,000 legal claims against the company.
Coloplast releases the interim financial report covering Q2 2013/14 on the 7 May
2014 where the above will in included in the financial guidance for the full year of
2013/14.
Lene Skole
CFO

Coloplast A/S

Investor Relations

CVR No.

Holtedam 1

Tel. +45 4911 1301

69749917

DK-3050 Humlebæk

Fax +45 4911 1555

Denmark

www.coloplast.com


For further information, please contact Investors and analysts

Lene Skole
Executive Vice President, CFO Tel. +45 4911 1700
Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com
Nick Fridberg
Sr. Investor Relations Manager
Tel. +45 4911 1800/+45 4911 1456
Email: dknf@coloplast.com

Press and the media

Ulla Lundhus
Head of Media and Positioning
Tel. +45 4911 1929
Email: dkul@coloplast.com
Simon Mehl Augustesen
Media Manager
Tlf. 4911 3488
Email: dksia@coloplast.com
This announcement is available in a Danish and an English -language version. In the event of discrepancies, the Danish version shall prevail.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2014-05 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. W orking closely with the people who use our products, we create solutions that are sensitive to their special needs. W e call this i n- timate healthcare.
Our business includes Ostomy Care, Urology Care, Continence Care and W ound and
Skin Care. We operate globally and employ more than 8,500 people.
2/2

distributed by